Literature DB >> 17927713

Prevalence of hepatic iron overload and association with hepatocellular cancer in end-stage liver disease: results from the National Hemochromatosis Transplant Registry.

Cynthia Ko1, Narendra Siddaiah, Jose Berger, Robert Gish, David Brandhagen, Richard K Sterling, Scott J Cotler, Robert J Fontana, Timothy M McCashland, Steven H B Han, Frederic D Gordon, Michael L Schilsky, Kris V Kowdley.   

Abstract

BACKGROUND: It is unclear whether mild to moderate iron overload in liver diseases other than hereditary haemochromatosis (HH) contributes to hepatocellular carcinoma. This study examined the association between hepatic iron grade and hepatocellular carcinoma in patients with end-stage liver disease of diverse aetiologies.
METHODS: The prevalence of hepatic iron overload and hepatocellular carcinoma was examined in 5224 patients undergoing liver transplantation. Explant pathology reports were reviewed for the underlying pathological diagnosis, presence of hepatocellular carcinoma and degree of iron staining. The distribution of categorical variables was studied using chi(2) tests.
RESULTS: Both iron overload and hepatocellular carcinoma were the least common with biliary cirrhosis (1.8 and 2.8% respectively). Hepatocellular carcinoma was the most common in patients with hepatitis B (16.7%), followed by those with hepatitis C (15.1%) and HH (14.9%). In the overall cohort, any iron overload was significantly associated with hepatocellular carcinoma (P=0.001), even after adjustment for the underlying aetiology of liver disease. The association between hepatic iron content and hepatocellular carcinoma was the strongest in patients with biliary cirrhosis (P<0.001) and hepatitis C (P<0.001).
CONCLUSIONS: Iron overload is associated with hepatocellular carcinoma in patients with end-stage liver disease, suggesting a possible carcinogenic or cocarcinogenic role for iron in chronic liver disease.

Entities:  

Mesh:

Year:  2007        PMID: 17927713     DOI: 10.1111/j.1478-3231.2007.01596.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  21 in total

1.  Iron Overload in Patients With Chronic Liver Disease.

Authors:  Kris V Kowdley
Journal:  Gastroenterol Hepatol (N Y)       Date:  2016-11

Review 2.  Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges.

Authors:  Yujin Hoshida; Bryan C Fuchs; Kenneth K Tanabe
Journal:  Curr Cancer Drug Targets       Date:  2012-11-01       Impact factor: 3.428

Review 3.  Secondary solid cancer screening following hematopoietic cell transplantation.

Authors:  Y Inamoto; N N Shah; B N Savani; B E Shaw; A A Abraham; I A Ahmed; G Akpek; Y Atsuta; K S Baker; G W Basak; M Bitan; Z DeFilipp; T K Gregory; H T Greinix; M Hamadani; B K Hamilton; R J Hayashi; D A Jacobsohn; R T Kamble; K A Kasow; N Khera; H M Lazarus; A K Malone; M T Lupo-Stanghellini; S P Margossian; L S Muffly; M Norkin; M Ramanathan; N Salooja; H Schoemans; J R Wingard; B Wirk; W A Wood; A Yong; C N Duncan; M E D Flowers; N S Majhail
Journal:  Bone Marrow Transplant       Date:  2015-03-30       Impact factor: 5.483

4.  Prevalence of Fatty Liver Disease and Hepatic Iron Overload in a Northeastern German Population by Using Quantitative MR Imaging.

Authors:  Jens-Peter Kühn; Peter Meffert; Christian Heske; Marie-Luise Kromrey; Carsten O Schmidt; Birger Mensel; Henry Völzke; Markus M Lerch; Diego Hernando; Julia Mayerle; Scott B Reeder
Journal:  Radiology       Date:  2017-05-05       Impact factor: 11.105

Review 5.  Iron-chelating therapy for transfusional iron overload.

Authors:  Gary M Brittenham
Journal:  N Engl J Med       Date:  2011-01-13       Impact factor: 91.245

Review 6.  Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma.

Authors:  Yujin Hoshida; Bryan C Fuchs; Nabeel Bardeesy; Thomas F Baumert; Raymond T Chung
Journal:  J Hepatol       Date:  2014-11-03       Impact factor: 25.083

Review 7.  The role of iron in the pathophysiology and treatment of chronic hepatitis C.

Authors:  Leslie Price; Kris V Kowdley
Journal:  Can J Gastroenterol       Date:  2009-12       Impact factor: 3.522

8.  TIMP3 deficiency exacerbates iron overload-mediated cardiomyopathy and liver disease.

Authors:  Pavel Zhabyeyev; Subhash K Das; Ratnadeep Basu; Mengcheng Shen; Vaibhav B Patel; Zamaneh Kassiri; Gavin Y Oudit
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-01-26       Impact factor: 4.733

9.  Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005.

Authors:  Sean F Altekruse; Katherine A McGlynn; Marsha E Reichman
Journal:  J Clin Oncol       Date:  2009-02-17       Impact factor: 44.544

Review 10.  Management of the thalassemias.

Authors:  Nancy F Olivieri; Gary M Brittenham
Journal:  Cold Spring Harb Perspect Med       Date:  2013-06-01       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.